Navigation Links
Scioderm Initiates Phase 2B Study of SD-101, A Novel Topical Therapy, for Patients with Epidermolysis Bullosa
Date:1/6/2014

DURHAM, N.C., Jan. 6, 2014 /PRNewswire/ -- Scioderm, Inc. today announced the initiation of a Phase 2B study designed to evaluate the efficacy and safety of SD-101, a novel topical therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a rare, genetic connective tissue disorder that typically manifests at birth or early childhood.

"People affected by EB suffer skin blisters, chronic wounds, almost constant pain and itching, and scarring," said Robert Ryan., Ph.D., President and Chief Executive Officer of Scioderm. "The current standard of care is palliative only and focuses primarily on daily wound care, bandaging and pain management. We believe SD-101 has the potential to initiate and continue healing of lesions in this patient population, and Scioderm is committed to develop SD-101 as expeditiously as possible as a treatment option for patients suffering from this devastating condition."

SD-101 for the treatment of EB has been granted an orphan drug designation in the US and in December 2013 received a positive opinion by the Committee for Orphan Medicinal Products (COMP) in the EU.  In addition, Scioderm was the first biotech to receive "Breakthrough Therapy" designation for SD-101 from the Food and Drug Administration (FDA) for the treatment of skin effects in patients with EB.  A breakthrough therapy designation conveys all of the fast track program features, as well as more intensive FDA guidance on an efficient drug development program. In addition, Scioderm was recently selected as  a 2013 "Fierce Top 15" company by FierceBiotech, considered as one of the top 15 emerging companies in the biotech industry. 

The Phase 2B study (SD-003) is a multi-site, prospective, randomized, placebo-controlled trial evaluating the efficacy and safety of SD-101 to close selected chronic cutaneous wounds and reduction in body surface area (
'/>"/>

SOURCE Scioderm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)
2. Scioderms Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
3. Scioderms SD-101 Receives Breakthrough Therapy Designation from FDA for Treatment of Epidermolysis Bullosa
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 The leading companies ... billion global cardiac rhythm management device market dominate ... that Medtronic, St. Jude Medical, Boston Scientific and ... this market segment. The healthcare market research publisher,s ... uses 2015 as a base year, providing forecasts ...
(Date:5/22/2015)... YORK , May 22, 2015  The ... of Zarxio (filgrastim-sndz) -- the first biosimilar product ... -- points toward growth in the contract ... The mainstream CMO industry is geared to the ... to produce major biopharmaceutical products. The healthcare market ...
(Date:5/22/2015)... May 22, 2015  The Mesothelioma Victims Center ... of mesothelioma get the best possible compensation, and they ... with this rare cancer caused by exposure to ... information related to treatment options such as a ... the Mesothelioma Victims Center anytime at 866-714-6466. ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5
... Company Focused on IND-Enabling Work with Protein Therapeutics that ... Modulate Alternative Pathway of Complement System, CAMBRIDGE, ... has initiated a corporate growth plan with the,appointment of ... of its headquarters in Cambridge, Mass. Dr. Celniker succeeds,Woodruff ...
... Nonin Medical, a leading innovator,of physiological monitoring solutions ... testing phase with its breakthrough technology to measure,regional ... is the continuous monitoring of the regional blood ... testing data and outcomes from an ongoing clinical ...
Cached Medicine Technology:Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2
(Date:5/26/2015)... 26, 2015 Writers and editors ... the Vasont® CCMS to make creating, editing, and ... top component content management system (CCMS) software provider, ... supports oXygen XML Editor Version 17.0, Syncro Soft’s ... Integrator extension merges key editorial functionality of the ...
(Date:5/26/2015)... The European imaging IT market will grow ... healthcare providers plan to make purchases. , Over 240 ... collected from these participants show that speech recognition is a ... seat. , “Many imaging IT vendors are poised to ... Jeremy Bikman. “This report details the European market in ways ...
(Date:5/26/2015)... 26, 2015 The Brain Aneurysm Foundation ... Pops and their renowned Conductor Keith Lockhart will once ... evening, June 10, 2015—the 4th Annual Brain Aneurysm ... Pops Night is set to feature an exclusive Brain ... Keith Lockhart who tragically lost his sister-in-law to a ...
(Date:5/25/2015)... TX (PRWEB) May 26, 2015 ... 2015” provides comprehensive information on the therapeutic development ... by identifying new targets and MOAs to produce ... 2015 pipeline review of Liver Failure with 22 ... 65 pages is available at http://www.rnrmarketresearch.com/liver-failure-pipeline-review-h1-2015-market-report.html ...
(Date:5/25/2015)... City, NY (PRWEB) May 26, 2015 ... (NAPW) honors Dr. Heather Stanley-Christian ... of the Year Circle. She is recognized with ... is the nation's leading networking organization exclusively for ... over 200 operating local chapters. , "I'm pleased ...
Breaking Medicine News(10 mins):Health News:Vasont Systems Certifies the Integration between the Vasont® Component Content Management System and oXygen® XML Editor 17.0 2Health News:peer60 report: European Healthcare IT Imaging Purchases: 2015 2Health News:Boston Pops & Renowned Conductor Keith Lockhart to Join the Brain Aneurysm Foundation for the 4th Annual Brain Aneurysm Foundation Night at the Pops 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:NAPW Inducts Dr. Heather Stanley-Christian, Systems Chair/Maternal Fetal Medicine at Stroger Hospital, into Its VIP Professional Woman of the Year Circle 2
... New Courses Improve Patient Care and Address State ... (Health Care Compliance,Strategies, Inc.), the leading provider of ... partnership with University,HealthSystem Consortium (UHC) to deliver a ... of 11 courses with multimedia content and,healthcare specific ...
... Irvine Department of Emergency Medicine is hosting the 11th ... 28-29 in Costa Mesa, Calif. As part of the ... findings on a variety of related areas ranging from ... the success of computerized alcohol-use counseling. , ...
... HARRISBURG, Pa., March 26 Governor Edward G.,Rendell today ... Pennsylvanians to begin planning ahead to better meet their ... not something that can be put off. If,people do ... expensive,consequences," Governor Rendell said. "The ,Own Your Future, campaign,empowers ...
... London and Hospital for Sick Kids purchase Open Access ... ... Open Biosystems, Inc.,announced today that two leading research institutions, University ... Canada, have,recently purchased access to Open Biosystems, shRNAmir technologies for,RNAi ...
... of pediatric liver transplant recipients report lower health-related ... after the surgery, compared to reports from the ... dysfunction fall within the normal range. These findings ... Transplantation. The article is also available online at ...
... 26 Target Data Research (TDR),President R.J. Slutz announced ... Forward fund raising campaign which will be held at ... support Step,N Forward and the Office of Public,Guardianship, Advanced ... quality of life and develop strategies to raise the ...
Cached Medicine News:Health News:HCCS Partners With UHC to Deliver Cultural Competency Courses 2Health News:HCCS Partners With UHC to Deliver Cultural Competency Courses 3Health News:UC Irvine researchers present latest findings at emergency medicine forum 2Health News:Governor Rendell Announces 'Own Your Future' Campaign; Urges Consumers to Better Plan Their Long-Term Care Needs 2Health News:Open Biosystems' Open Access RNAi Program Continues to Gain Momentum Worldwide 2Health News:Open Biosystems' Open Access RNAi Program Continues to Gain Momentum Worldwide 3Health News:Study shows lifetime effects of pediatric liver transplants 2
HYDRACLEAR is our brandname for a remarkable moisture rich element that lies throughout the interior and exterior of the ACUVUE ADVANCE Brand Contact Lenses creating a unique soft, silky feel....
... For use in the percutaneous retrieval of ... or wire guides, and other foreign objects. ... snare around the lead body. It is delivered ... long, flexible 12 Fr cannula that is placed ...
... existing patented technologies such as Simtec ... with the new innovations of automated ... determination, and intelligent collision avoidance in ... treatment delivery with enhanced patient safety. ...
Clinac EX Platinum accelerators offer all the high performance features of the EX series and come standard with the latest high-precision dose sculpting technology for advanced tumor control....
Medicine Products: